Provectus Biopharmaceutica Debt
| PVCTDelisted Stock | USD 0.11 0.00 0.00% |
Provectus Biopharmaceutica holds a debt-to-equity ratio of 0.25. . Provectus Biopharmaceutica's financial risk is the risk to Provectus Biopharmaceutica stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Provectus Biopharmaceutica's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Provectus Biopharmaceutica's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the OTC Stock is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Provectus OTC Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Provectus Biopharmaceutica's stakeholders.
For most companies, including Provectus Biopharmaceutica, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Provectus Biopharmaceuticals, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Provectus Biopharmaceutica's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Provectus Biopharmaceutica's debt-to-equity ratio measures a OTC Stock's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Provectus Biopharmaceutica is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Provectus Biopharmaceutica to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Provectus Biopharmaceutica is said to be less leveraged. If creditors hold a majority of Provectus Biopharmaceutica's assets, the OTC Stock is said to be highly leveraged.
Provectus |
Provectus Biopharmaceutica Debt to Cash Allocation
Provectus Biopharmaceuticals currently holds 2.29 M in liabilities with Debt to Equity (D/E) ratio of 0.25, which may suggest the company is not taking enough advantage from borrowing. Provectus Biopharmaceutica has a current ratio of 0.26, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Provectus Biopharmaceutica until it has trouble settling it off, either with new capital or with free cash flow. So, Provectus Biopharmaceutica's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Provectus Biopharmaceutica sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Provectus to invest in growth at high rates of return. When we think about Provectus Biopharmaceutica's use of debt, we should always consider it together with cash and equity.Provectus Biopharmaceutica Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Provectus Biopharmaceutica's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Provectus Biopharmaceutica, which in turn will lower the firm's financial flexibility.Provectus Biopharmaceutica Corporate Bonds Issued
Understaning Provectus Biopharmaceutica Use of Financial Leverage
Provectus Biopharmaceutica's financial leverage ratio measures its total debt position, including all of its outstanding liabilities, and compares it to Provectus Biopharmaceutica's current equity. If creditors own a majority of Provectus Biopharmaceutica's assets, the company is considered highly leveraged. Understanding the composition and structure of Provectus Biopharmaceutica's outstanding bonds gives an idea of how risky it is and if it is worth investing in.
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. Provectus Biopharmaceuticals, Inc. was incorporated in 2002 and is based in Knoxville, Tennessee. Provectus Pharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 4 people. Please read more on our technical analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Provectus Biopharmaceutica information on this page should be used as a complementary analysis to other Provectus Biopharmaceutica's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Other Consideration for investing in Provectus OTC Stock
If you are still planning to invest in Provectus Biopharmaceutica check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Provectus Biopharmaceutica's history and understand the potential risks before investing.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.